Patient characteristics
| Pretreatment Characteristics . | No. of Patients (n = 58) . |
|---|---|
| Indication for BMT | |
| CML | 30 |
| AML | 26 |
| ALL | 10 |
| Other* | 5 |
| Indication for UDLI | |
| CML | 25 |
| AML | 23 |
| ALL | 7 |
| Other† | 3 |
| Years of age at UDLI, median (range) | 26 (2-60) |
| HLA match grade | |
| Matched | 46 |
| Mismatched | 12 |
| Donor sex match | |
| Same sex | 32 |
| Sex mismatch | 26 |
| Acute GVHD after BMT | |
| Grade 0 | 32 |
| Grade I | 10 |
| Grade II | 10 |
| Grade III-IV | 6 |
| Chronic GVHD after BMT | 18 |
| T-cell depletion of bone marrow | |
| Yes | 30 |
| No | 28 |
| Weeks, BMT to relapse, median (range) | 40 (8-295) |
| Weeks, relapse to UDLI, median (range) | 7 (0.1-72) |
| Weeks, BMT to UDLI | 47 (12-297) |
| MNC dose × 108/kg, median (range) | |
| All patients | 1.0 (0.001-31.8) |
| CML | 0.85 (0.005-5.21) |
| AML | 1.34 (0.001-31.8) |
| ALL | 0.9 (0.08-10.9) |
| Other | 1.77 (1.45-7.0) |
| Pretreatment Characteristics . | No. of Patients (n = 58) . |
|---|---|
| Indication for BMT | |
| CML | 30 |
| AML | 26 |
| ALL | 10 |
| Other* | 5 |
| Indication for UDLI | |
| CML | 25 |
| AML | 23 |
| ALL | 7 |
| Other† | 3 |
| Years of age at UDLI, median (range) | 26 (2-60) |
| HLA match grade | |
| Matched | 46 |
| Mismatched | 12 |
| Donor sex match | |
| Same sex | 32 |
| Sex mismatch | 26 |
| Acute GVHD after BMT | |
| Grade 0 | 32 |
| Grade I | 10 |
| Grade II | 10 |
| Grade III-IV | 6 |
| Chronic GVHD after BMT | 18 |
| T-cell depletion of bone marrow | |
| Yes | 30 |
| No | 28 |
| Weeks, BMT to relapse, median (range) | 40 (8-295) |
| Weeks, relapse to UDLI, median (range) | 7 (0.1-72) |
| Weeks, BMT to UDLI | 47 (12-297) |
| MNC dose × 108/kg, median (range) | |
| All patients | 1.0 (0.001-31.8) |
| CML | 0.85 (0.005-5.21) |
| AML | 1.34 (0.001-31.8) |
| ALL | 0.9 (0.08-10.9) |
| Other | 1.77 (1.45-7.0) |